Post-pregnancy anti-TNF therapy with several guidelines … lasting benefit

According to one study, continuing treatment with anticancer necrosis factor (anti-TNF) after 24 weeks of gestation not only reduces the risk of inflammatory bowel disease (IBD) recurrence in pregnant women, but also reduces premature birth.

The results of a study on the prognosis of anti-TNF therapy in pregnant women with inflammatory bowel disease, conducted by Professor Antoine Meyer of the Paris public hospital in France, were published on the 26th in the International Journal of Internal Medicine ( doi.org /10.7326/M22-0819) (doi.org/10.7326/M22-0819)).

About 3.3 million people in North America and 3.2 million people in Europe have Crohn’s disease or ulcerative colitis, which often affects young women during their reproductive years.

data photo

The problem is that North American guidelines recommend continuing anti-TNF therapy during pregnancy, while European guidelines recommend stopping anti-TNF therapy for about 24 weeks.

Researchers analyzed data from the French National Health Data System (Systeme National des Donnees de Sante) which used anti-TNF after 24 weeks of pregnancy between 2010 and 2020 to examine changes in maternal, pregnancy prognosis. and of the newborn during early pregnancy.

The researchers examined whether IBD recurred up to six months after conception, the negative consequences for pregnancy and serious infections in children during the first five years of life.

Of the 184,115 women with IBD, 68,209 became pregnant between April 2010 and December 2020. Among these, 5413 patients received anti-TNF treatment before and after 24 weeks. TNF treatment was discontinued in 2,890 patients (54.6%) before 24 weeks and continued for more than 24 weeks in 2403 patients (45.4%).

As a result of the analysis, the efficacy of anti-TNF treatment was observed in the reduction of the relapse rate of maternal IBD (35.8% vs. 39.0%) and in the flank of the continuation of anti-TNF treatment for childbirth. premature (7.6% versus 8.99%).

In stillbirths (0.4% vs 0.2%), low body weight (13.1% vs 12.9%), and infectious stillbirths (0.4% vs 0.2%), no difference was found based on the duration of the anti-TNF.

“The duration of anti-TNF after 24 weeks of gestation did not affect neonatal outcomes or severe infections,” the researchers concluded.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.